February 5, 2020 07:28 AM ESTUpdated 01:10 PM

China researchers tout in vitro data for Gilead's antiviral against Wuhan virus — which they are trying to patent

Amber Tong

There’s no definitive proof yet that Gilead’s remdesivir works as a treatment for 2019-nCov, but researchers in China clearly consider it promising enough to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

China researchers tout in vitro data for Gilead's antiviral against Wuhan virus — which they are trying to patent

Amber Tong

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Merck KGaA closes in on SpringWorks deal at $3.5B price point

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Chi­na re­searchers tout in vit­ro da­ta for Gilead­'s an­tivi­ral against Wuhan virus — which they are try­ing to patent

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

China researchers tout in vitro data for Gilead's antiviral against Wuhan virus — which they are trying to patent